Deprescribing—reducing or stopping medications when risks outweigh benefits—need not improve disease outcomes to provide clinical value. The practice delivers measurable benefits through reduced adverse effects, improved quality of life, and lower costs, making it a valid optimization strategy independent of disease-specific efficacy metrics.
Key Points
- Deprescribing benefits extend beyond disease outcomes to quality of life
- Reduced medication burden decreases adverse drug reaction risk over time
- Cost reduction and improved outcomes can coexist without traditional efficacy gains
Longevity Analysis
Deprescribing reframes medication management as a functional optimization problem rather than purely a disease-suppression exercise. By removing chemical stressors that compromise resilience—particularly the cumulative burden of drug interactions and iatrogenic effects—deprescribing addresses interference at the foundation level. This approach recognizes that longevity is not achieved through maximizing pharmaceutical interventions but through minimizing what interferes with the body's capacity to adapt and regenerate. The practice directly supports defense and detoxification functions by reducing the metabolic and immunological load imposed by unnecessary medications, allowing these systems to allocate resources more efficiently toward repair and sustained homeostasis.
Original published by The Lancet Healthy Longevity, by Catherine S Hwang, Kenneth S Boockvar, Michael A Steinman.